Authors
Robert J. Nordyke, PhD, is a Principal and Senior Advisor in the Pharmaceutical Commercialization practice at BlueRidge Life Sciences, where he leads policy research and evidence generation to support market access and value demonstration. He has over 25 years of experience across health economics, policy research, HTA, and product commercialization at drug manufacturers, consultancies, and policy research groups. Bob holds engineering degrees from Rose‑Hulman Institute of Technology and the University of Texas at Austin, and a PhD from the RAND Graduate School of Public Policy.
Advertisement
Advertisement
Trending on AJMC
1
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
2
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5

